Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by driver mutations in other genes. METHODS: Five hundred and fourteen consecutive patients with NSCLC of all stages were tested...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobsen, Jan Nyrop, Santoni-Rugiu, Eric, Grauslund, Morten, Melchior, Linea, Sørensen, Jens Benn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995236/
https://www.ncbi.nlm.nih.gov/pubmed/29899852
http://dx.doi.org/10.18632/oncotarget.25490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995236/
https://www.ncbi.nlm.nih.gov/pubmed/29899852
http://dx.doi.org/10.18632/oncotarget.25490

Ejemplares similares